Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioXcel Therapeutics stock

Own BioXcel Therapeutics stock in just a few minutes.

BioXcel Therapeutics, Inc is a biotechnology business based in the US. BioXcel Therapeutics shares (BTAI) are listed on the NASDAQ and all prices are listed in US Dollars. BioXcel Therapeutics employs 50 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in BioXcel Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BTAI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

BioXcel Therapeutics share price

Use our graph to track the performance of BTAI stocks over time.

BioXcel Therapeutics shares at a glance

Information last updated 2021-04-30.
52-week range$31.84 - $67.74
50-day moving average $39.19
200-day moving average $47.57
Wall St. target price$102.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.77

Buy BioXcel Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BioXcel Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioXcel Therapeutics financials

Gross profit TTM $0
Return on assets TTM -39.57%
Return on equity TTM -70.35%
Profit margin 0%
Book value $8.47
Market capitalisation $846.3 million

TTM: trailing 12 months

Shorting BioXcel Therapeutics shares

There are currently 3.7 million BioXcel Therapeutics shares held short by investors – that's known as BioXcel Therapeutics's "short interest". This figure is 8.9% up from 3.4 million last month.

There are a few different ways that this level of interest in shorting BioXcel Therapeutics shares can be evaluated.

BioXcel Therapeutics's "short interest ratio" (SIR)

BioXcel Therapeutics's "short interest ratio" (SIR) is the quantity of BioXcel Therapeutics shares currently shorted divided by the average quantity of BioXcel Therapeutics shares traded daily (recently around 565252.16718266). BioXcel Therapeutics's SIR currently stands at 6.46. In other words for every 100,000 BioXcel Therapeutics shares traded daily on the market, roughly 6460 shares are currently held short.

However BioXcel Therapeutics's short interest can also be evaluated against the total number of BioXcel Therapeutics shares, or, against the total number of tradable BioXcel Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioXcel Therapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 BioXcel Therapeutics shares in existence, roughly 150 shares are currently held short) or 0.2455% of the tradable shares (for every 100,000 tradable BioXcel Therapeutics shares, roughly 246 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioXcel Therapeutics.

Find out more about how you can short BioXcel Therapeutics stock.

BioXcel Therapeutics share dividends

We're not expecting BioXcel Therapeutics to pay a dividend over the next 12 months.

BioXcel Therapeutics share price volatility

Over the last 12 months, BioXcel Therapeutics's shares have ranged in value from as little as $31.84 up to $67.74. A popular way to gauge a stock's volatility is its "beta".

BTAI.US volatility(beta: 1.21)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioXcel Therapeutics's is 1.2129. This would suggest that BioXcel Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

BioXcel Therapeutics overview

BioXcel Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site